Top Page
Ayr Wellness
(OTC:AYR.A)
Ayr Wellness (AYR.A) vs. iShares MSCI Canada ETF (EWC)
Ayr Wellness Business Overview & Revenue Model
Ayr Wellness Earnings Call Summary
Ayr Wellness Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 463.63M | 463.63M | 465.62M | 357.61M | 155.11M |
| Gross Profit | 176.68M | 202.44M | 190.44M | 138.10M | 103.10M |
| EBITDA | -154.53M | 84.60M | -67.66M | 87.69M | 17.21M |
| Net Income | -359.31M | -272.43M | -245.47M | -16.95M | -176.33M |
Balance Sheet | |||||
| Total Assets | 1.27B | 1.46B | 1.76B | 1.86B | 615.87M |
| Cash, Cash Equivalents and Short-Term Investments | 35.48M | 50.77M | 80.64M | 154.34M | 127.24M |
| Total Debt | 621.88M | 597.77M | 621.66M | 483.82M | 190.62M |
| Total Liabilities | 904.31M | 889.20M | 928.56M | 839.85M | 465.01M |
| Stockholders Equity | 379.53M | 581.78M | 833.32M | 1.02B | 150.86M |
Cash Flow | |||||
| Free Cash Flow | -15.14M | -12.44M | -96.66M | -127.78M | 21.74M |
| Operating Cash Flow | 9.63M | 27.16M | -34.16M | -27.78M | 36.51M |
| Investing Cash Flow | -21.81M | -24.15M | -66.50M | -219.63M | -62.25M |
| Financing Cash Flow | -3.10M | -32.89M | 26.96M | 274.51M | 144.57M |
Ayr Wellness Technical Analysis
Ayr Wellness Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.34B | -0.07 | -63.86% | 2.34% | 16.17% | 0.23% | |
40 Underperform | $18.10M | ― | -74.75% | ― | 1.48% | -174.61% | |
| ― | $195.95M | 21.32 | 4.76% | ― | ― | ― | |
| ― | $140.98M | 8.49 | 18.60% | ― | ― | ― | |
| ― | $21.16M | ― | -16.22% | ― | ― | ― | |
| ― | $59.23M | ― | -39.53% | ― | ― | ― | |
58 Neutral | C$177.60M | ― | -38.89% | ― | -6.80% | 11.94% |
Ayr Wellness Corporate Events
AYR Wellness has announced an extension to its Limited Waiver Agreement with its senior noteholders, extending the temporary waiver period to July 25, 2025. This extension provides AYR with additional time to negotiate with its senior lenders and explore strategic options to strengthen its capital structure. The waiver addresses defaults related to delayed financial filings and payment issues, allowing AYR to continue discussions and assess financial strategies without immediate default repercussions. The company remains committed to operating normally and evaluating growth opportunities in key markets.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness has extended its Limited Waiver Agreement with its senior noteholders to July 18, 2025, allowing more time for negotiations and strategic planning to strengthen its capital structure. This extension provides temporary relief from default-related actions, enabling AYR to continue its operations and explore growth opportunities while addressing its financial obligations.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness Inc. has received a Notification of Disposition of Collateral from an agent under a Pledge Agreement, indicating potential reclamation and sale of its interest in PA Natural Medicine LLC due to alleged defaults. Additionally, AYR has extended a Limited Waiver Agreement with senior noteholders to July 11, 2025, allowing more time for negotiations and exploration of strategic options to strengthen its capital structure, though it does not constitute a permanent waiver of defaults.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness has announced that it did not make the interest payment due on its senior notes by June 30, 2025, which could lead to a default if not addressed by July 30, 2025. The company is actively engaged in discussions with noteholders to explore capital structure alternatives as part of a strategic review. Despite the missed payment, AYR does not expect any operational disruptions, indicating a focus on restructuring its debt profile to achieve a more sustainable financial position.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness has announced a delay in filing its interim financial statements for Q1 2025 due to ongoing negotiations with creditors and the assessment of debt obligations. This delay has resulted in a failure-to-file cease-trade order from the Ontario Securities Commission, halting trading of AYR’s securities in Canada until the filings are completed and requirements are met.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness has extended its Limited Waiver Agreement with senior noteholders, allowing more time to address financial obligations. This extension provides the company with additional flexibility to negotiate with lenders and explore strategic options to strengthen its capital structure, although it does not permanently resolve existing defaults.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness Inc. has announced a delay in filing its interim financial statements for the first quarter of 2025 due to ongoing negotiations with creditors and the assessment of debt obligations. This delay has led to a failure-to-file cease-trade order from the Ontario Securities Commission, suspending trading of AYR’s securities in Canadian jurisdictions. Despite this, AYR does not anticipate any impact on its regular operations and is working to complete the filings promptly, with an update expected by June 27, 2025.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness Inc. has entered into a Limited Waiver Agreement with the majority of its senior secured noteholders, providing a temporary waiver for certain defaults related to delayed financial filings and payment obligations. This agreement grants AYR additional time to negotiate with senior lenders and explore strategic alternatives to address its capital structure, while maintaining its business operations and commitment to delivering quality cannabis products.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness Inc. has announced an update regarding the status of its securities following a delay in filing its interim financial statements for the quarter ending March 31, 2025. As a result of the delay, the Ontario Securities Commission has issued a Failure to File Cease Trade Order, prohibiting trading of the company’s securities in Canada, with limited exceptions. AYR is actively working to resolve the issue and does not anticipate any disruption to its regular operations or its commitment to delivering quality cannabis products.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.75 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.
AYR Wellness Inc. announced a delay in filing its Q1 2025 financial statements and management discussion due to ongoing strategic review processes and negotiations with creditors. The Ontario Securities Commission will issue a cease-trade order, halting trading of AYR’s securities in Canada until the filings are completed, which is expected by June 13, 2025. Despite this, AYR does not anticipate any impact on its regular operations.
The most recent analyst rating on ($TSE:AYR.A) stock is a Buy with a C$3.50 price target. To see the full list of analyst forecasts on Ayr Wellness stock, see the TSE:AYR.A Stock Forecast page.